AETHELGARD / TREASURY & CAPITAL
AUDIT READY
✓ GAAP/IFRS COMPLIANT
00:00:00 LCL
TREASURY INTELLIGENCE / CAPITAL ALLOCATION

Intercompany Treasury & Consolidated Cash Flow

Capital pipeline monitoring, ROI simulation, transfer pricing control and subsidiary liquidity analysis.

MODULE 06 / 06
REPORTING GAAP / IFRS
Total Inflow (MTD)
$2.26M
+8.4% VS LAST MONTH
Tax Provision
$285K
Q3 SCHEDULED
Intercompany Eliminations
$605K
3 TX ELIMINATED
Net Free Cash Flow
$1.37M
POST-TAX CONSOLIDATED
Intercompany Capital Flow Pipelines
Live Sync
Aethel-Labs → Aethel-Health  (Software Licensing)
$420,000
65% of license cap · cleared Q2
Aethel-Retail → Aethelgard Group  (Dividend Upstream)
$1,250,000
88% of declared dividend · remitted
Aethel-Health → Aethelgard Group  (Management Fees)
$310,000
45% disbursed · remaining Q3
Aethelgard Group → Tax Provision Reserve
$285,000
38% set aside · statutory deadline Aug 2026
Cash Flow Breakdown
Cash flow: Dividends 55%, Licensing 19%, Mgmt Fees 14%, Tax Reserve 12%.
Dividends 55% Licensing 19% Mgmt Fees 14% Tax Reserve 12%
Pipeline sync: pandas .groupby() active Currency Base: USD ($)
Capital Injection ROI Simulator
Capital Injection Amount $500,000
Target Subsidiary
Projected Output
Projected Annual ROI 24.8%
Est. Payback Period 4.0 Years
Net Return (5Y) $620,000
Subsidiary Liquidity Health
Transfer Pricing Ledger
Intercompany transactions · elimination filter active
Transaction ID From (Debtor) To (Creditor) Description Amount Treatment
Quarterly Consolidated Cash Flow Trend
FY 2025 — Q2 2026
Quarterly cash flow data.
Aethel-Health Aethel-Retail Aethel-Labs
Treasury AI
[TREASURY] Terminal initialized.
Type health, retail, or labs to inject capital into a subsidiary. Type dark/light for the theme.